Non-FDG PET imaging of brain tumors

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Non-FDG PET imaging of brain tumors

HUANG Zemin，

GUAN Yihui，

ZUO Chuantao，

ZHANG Zhengwei，

XUE Fangping，

LIN Xiangtong

Nuclear Science and Techniques

Vol.18, No.3

pp.154-158

Published in print 20 Jun 2007

DOI：10.1016/S1001-8042(07)60038-4

CLC：R817.4,R739.41

31300

Due to relatively high uptake of glucose in the brain cortex, the use of FDG PET imaging is greatly limited in brain tumor imaging, especially for low-grade gliomas and some metastatic tumours. More and more tracers with higher specificity were developed lately for brain tumor imaging. There are 3 main types of non-FDG PET tracers: amino acid tracers, choline tracers and nucleic acid tracers. These tracers are now widely applied in many aspects of brain tumor imaging. This article summarized the general use of non-FDG PET in different aspects of brain tumor imaging.

Positron emission tomographyBrain tumorNon-FDG

References

[1]

Chung J K, Kim Y K, Kim S K, et al. Eur J Nucl Med Mol Imaging, 2002, 29(2): 176-182.

[2]

Herholz K, Holzer T, Bauer B, et al. Neurology, 1998, 50: 1321-1322.

[3]

Ishiwata K, Enomoto K, Sasaki T, et al. J Nucl Med, 1996, 37: 279-285.

[4]

Langen K J, Muhlensiepen H, Holschbach M, et al. J Nucl Med, 2000, 41: 1250-1255.

[5]

Kracht L W, Friese M, Herholz K, et al. Eur J Nucl Med Mol Imaging, 2003, 30: 868-873.

[6]

Sato N, Suzuki M, Kuwata N, et al. Neurosurg Rev, 1999, 22: 210-214.

[7]

Iuchi T, Iwadate Y, Namba H, et al. Neurol Res, 1999, 21(7): 640-644.

[8]

Giammarile F, Cinotti LE, Jouvet A, et al. J Neurooncol, 2004, 68(3): 263-274.

[9]

Sunada I, Tsuyuguchi N, Hara M, et al. Radiation Medicine, 2002, 20(2): 97-100.

[10]

Jacobs A. Stroke, 1995, 26: 1859-1866.

[11]

Rau F C, Weber W A, Wester H-J, et al. Eur J Nucl Med, 2002, 29: 1039-1046.

[12]

Kaim A H, Weber B, Kurrer M O, et al. Eur J Nucl Med, 2002, 29: 648-654.

[13]

Weber W A, Wester H-J, Grosu A L, et al. Eur J Nucl Med Mol Imaging, 2000, 27(5): 542-549.

[14]

Frank W F, Dirk P, Hans-Jörg W, et al. J Neurosurg, 2005, 102: 318-327.

[15]

Pauleit D, Stoffels G, Schaden W, et al. J Nucl Med, 2005, 46(3): 411-416.

[16]

Ohtani T, Kurihara H, Ishiuchi S, et al. Eur J Nucl Med, 2001, 28: 1664-1670.

[17]

Kwee SA, Coel MN, Lim J, et al. J Neuroimaging, 2004, 14: 285-289.

[18]

Tian Mei, Zhang Hong, Oriuchi N, et al. Eur J Nucl Med Mol Imaging, 2004, 31: 1064-1072.

[19]

Zhang H, Tian M, Oriuchi N, et al. Nucl Med Commun, 2003, 24: 273-279.

[20]

Kong X B, Zhu Q Y, Vidal P M, et al. Antimicrob Agents Chemother, 1992, 36: 808-818.

[21]

Sherley J L, Kelly T J. J Biol Chem, 1988, 263: 8350-8358.

[22]

Hengstschlager M, Knofler M, Mullner E W, et al. J Biol Chem, 1994, 269: 13836-13842.

[23]

Toyohara J, Waki A, Takamatsu S, et al. Nucl Med Biol, 2002, 29: 281-287.

[24]

Rasey J S, Grierson J R, Wiens L W, et al. J Nucl Med, 2002, 43: 1210-1217.

[25]

Chen W, Cloughesy T, Kamdar N, et al. J Nucl Med, 2005, 46(6): 945-952.

[26]

Jacobs A H, Thomas A, Kracht L W, et al. J Nucl Med, 2005, 46(12): 1948-1958.

[27]

Pirotte B, Goldman S, Massager N, et al. J Neurosurg, 2004, 101(3): 476-483.

[28]

Pirotte B, Goldman S, Massager N, et al. J Nucl Med, 2004, 45(8): 1293-1298.

[29]

Grosu A L, Weber W A, Franz M, et al. Int J Radiat Oncol Biol Phys, 2005, 63(2): 511-519.

[30]

Ribom D, Engler H, Blomquist E, et al. Eur J Nucl Med Mol Imaging, 2002, 29(5): 632-640.

[31]

Kim S, Chung J K, Im S H, et al. Eur J Nucl Med Mol Imaging, 2005, 32(1): 52-59.

[32]

Van Laere K, Ceyssens S, Van Calenbergh F, et al. Eur J Nucl Med Mol Imaging, 2005, 32(1): 39-51.

[33]

Walter R, Claudia G, Gabriele P, et al. Neurosurgery, 2005, 57: 505-511.